How Analysts Feel About GlycoMimetics, Inc. (GLYC) After Today’s Significant Increase?

Investors sentiment increased to 1.32 in 2019 Q1. Its up 0.26, from 1.06 in 2018Q4. It increased, as 7 investors sold GlycoMimetics, Inc. shares while 21 reduced holdings. 10 funds opened positions while 27 raised stakes. 44.56 million shares or 0.36% more from 44.40 million shares in 2018Q4 were reported.
Jgp Gestao De Recursos Ltda has 10,088 shares for 0.05% of their portfolio. Moore Cap Mgmt Lp reported 0.02% of its portfolio in GlycoMimetics, Inc. (NASDAQ:GLYC). Jennison Associate Ltd accumulated 1.42 million shares. National Bank & Trust Of Ny Mellon, New York-based fund reported 146,362 shares. Fmr Limited Liability Com owns 3.90 million shares. Td Asset Mngmt Inc reported 74,310 shares. Fincl Bank Of America De, North Carolina-based fund reported 28,229 shares. Moreover, Barclays Public Limited Com has 0% invested in GlycoMimetics, Inc. (NASDAQ:GLYC). Axa invested in 0.05% or 925,144 shares. Jefferies Grp Inc Ltd Liability invested in 59,605 shares. Franklin invested 0.01% in GlycoMimetics, Inc. (NASDAQ:GLYC). Citigroup has invested 0% in GlycoMimetics, Inc. (NASDAQ:GLYC). Dimensional Fund Advisors L P holds 866,962 shares. Sphera Funds Mngmt holds 311,013 shares or 0.36% of its portfolio. Deutsche Bank Ag owns 21,392 shares.

The stock of GlycoMimetics, Inc. (NASDAQ:GLYC) is a huge mover today! The stock increased 4.81% or $0.14 during the last trading session, reaching $3.05. About 1.71M shares traded or 113.04% up from the average. GlycoMimetics, Inc. (NASDAQ:GLYC) has declined 32.63% since August 15, 2018 and is downtrending. It has underperformed by 32.63% the S&P500.
The move comes after 5 months positive chart setup for the $131.74M company. It was reported on Aug, 15 by Barchart.com. We have $3.17 PT which if reached, will make NASDAQ:GLYC worth $5.27M more.

GlycoMimetics, Inc. (NASDAQ:GLYC) Ratings Coverage

Among 3 analysts covering GlycoMimetics (NASDAQ:GLYC), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. GlycoMimetics has $23 highest and $500 lowest target. $11.33’s average target is 271.48% above currents $3.05 stock price. GlycoMimetics had 9 analyst reports since February 28, 2019 according to SRatingsIntel. The firm has “Hold” rating given on Monday, August 5 by SunTrust. Piper Jaffray downgraded GlycoMimetics, Inc. (NASDAQ:GLYC) on Monday, August 5 to “Neutral” rating. H.C. Wainwright maintained GlycoMimetics, Inc. (NASDAQ:GLYC) on Thursday, March 7 with “Buy” rating.

More notable recent GlycoMimetics, Inc. (NASDAQ:GLYC) news were published by: Schaeffersresearch.com which released: “GLYC Stock Sliced in Half on Disappointing Drug Data – Schaeffers Research” on August 05, 2019, also Seekingalpha.com with their article: “Lexicon Pharmaceuticals and MediWound among healthcare gainers; GlycoMimetics leads the losers – Seeking Alpha” published on August 05, 2019, Nasdaq.com published: “Are Options Traders Betting on a Big Move in GlycoMimetics (GLYC) Stock? – Nasdaq” on August 08, 2019. More interesting news about GlycoMimetics, Inc. (NASDAQ:GLYC) were released by: Seekingalpha.com and their article: “GlycoMimetics’ lead drug flunks late-stage study; shares down 54% premarket – Seeking Alpha” published on August 05, 2019 as well as Benzinga.com‘s news article titled: “70 Biggest Movers From Yesterday – Benzinga” with publication date: August 06, 2019.

GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. The company has market cap of $131.74 million. The firm is developing its lead product candidates include rivipansel, a pan-selectin antagonist, which is in Phase III clinical trials for the treatment of vaso-occlusive crisis, a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease; and GMI-1271, an E-selectin antagonist to treat acute myeloid leukemia and other hematologic cancers. It currently has negative earnings. It is also developing GMI-1359, a drug candidate targeting E-selectin and CXCR4; and galectin-3 and galectin-9 inhibitors.

GlycoMimetics, Inc. (NASDAQ:GLYC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.